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FORMULATION AND EVALUATION OF FAST DISSOLVING TABLETS 
ALONG WITH ANTIEPILEPTIC DRUGS 
 
Abstract 
The objective of present study was to prepare and evaluate the mouth dissolving tablet 
of lacosamide using super disintegrant like Guar Gum, and other excipients like 
microcrystalline cellulose and mannitol in different concentrations by direct 
compressionmethod. Lacosamide has been shown to be an effective antiepileptic agent 
appropriate for epilepsy patients. Effect of different formulation variables; asamount 
and type of polymer were studied,on release profile and other characteristics. The 
mouth dissolving tablets were prepared by single punch machine using powder blend of 
superdisintegrant and lacosamide. Post-compression parameters like hardness, weight 
variation, friability,in-vitrodispersion, drug content uniformity and in-vitro drug 
releasestudies were carried out for all formulations. All formulationsresultswere 
withinofficial limits.Fast disintegration time obtained between 35sec. and 128 
sec,was within official limit.Different drug release kinetic modelswere applied for 
selecting batchesfor stability studies.These showed that there was no any significant 
change in residual drug content inmouth dissolving tablets. By the in-vitro 
disintegration, it is concluded that formulation prepared by Guar Gum (10%) 
showedfaster disintegration time than that ofMCC.This indicates that the use of 
super disintegrants increases the release of drug from the formulation. Therefore, it 
can be concluded thatsuch mouth dissolving tablets aresuitable delivery system 
forlacosamide. Thus; the objective of this study was achieved. Thus, the “patient-
friendly dosage form” especially for pediatrics, geriatrics, bedridden and non-
cooperative patients, can be successfully formulated using this technology, providing 
faster and better drug release, thereby, improving the bioavailability of drug compared 
to conventional marketed formulations. 
Keywords: Lacosamide, Epilepsy, Fast dissolving tablet, Superdisintegrants, 
Bioavailability, Pre-compression parameters, Post-compression parameters. 
 
Introduction  
Epilepsy is one of the most common central nervous system (neurological) disorders, 
resulting from stagesof abnormal, excessive generationof neuronal disturbances in the 
brain. Epilepsyis a brain disorder that is identifiedby chronic epileptic seizures. 
Epileptic seizures result from sudden repetitiveoccurrence of sensory disturbance, 
causingloss of consciousness, or convulsions, associated with abnormal electrical 
activity in the brain.About90% of epilepsy patients are found in developing 
countries. 
Causes of epilepsy 
There are defined causes of epilepsy that are common in different age groups; 
1. In neonatal period and early infancy, the most common causes are hypoxic–ischemic 
encephalopathy, CNS infections, trauma, congenital CNS abnormalities and metabolic 
disorder. 
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2. In late infancy and early childhood, the most common febrile seizures may be caused 
by CNS infections and trauma. 
Pathophysiology of epilepsy 
Seizures are paroxysmal manifestations of cerebral cortex. Theyoccurwhen a sudden 
imbalance occurs between the excitatory and inhibitory forces within the network of 
corticalneurons. Cell membraneinstability or its physiological changes in its 
adjacent supporting cells represent the main pathophysiology of seizures. 
 
 
Fig.1 Stages of Seizure 
 
Classification of seizures 
1. Generalized Seizures 
A. Absence seizures (formerly called petit mal) 
B. Myoclonic seizures 
C. Clonic seizures 
D. Tonic seizures 
E. Tonic clonic seizures (formerly called grand mal) 
F. Atonic seizures (drop attacks) 
 
2. Partial Seizures 
A. Simple partial seizures (consciousness not impaired) 
1. with motor symptoms 
2. with sensory symptoms 
3. with autonomic symptoms 
4. with psychic symptoms 
B. Complex partial seizures (with impaired consciousness) 
l. simple partial seizures followed by impairment of consciousness 
2. with impairment of consciousness at seizure onset 
 
C. Partial seizures evolving to secondarily generalized seizures 
1. simple partial secondarily generalized 
2. complex partial secondarily generalized 
3. simple partial evolving to complex partial evolving to generalized 
 
Fast dissolving tablet 
Although, tablets are themost commonly used dosage form because of itssimplicity 
ofself-administration, ease of preparation, and accuracy of dose 
delivery,however;pediatrics and geriatricsmay suffer difficulty in 
swallowing(dysphasia) or chewing. 
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                                      Fig. 2 Conceptual diagram of FDT 
 
Need for Development of fast dissolving tablets FDTs: 
Table 1. Patients related factors for development of FDTs 
 
Various effectiveness factors are as follows: 
 Increased bioavailability and faster onset of action are major claim of these 
formulations. 
Various Manufacturing and marketing factors are as follows: 
 Developing new drug delivery technologies and utilizing them in product 
development is critical for pharmaceutical industries to survive, regardless of 
their size. 
Materials and Methods 
Drug profile: Lacosamide 
Synonyms: Erlosamide, Harkoseride, Lacosamida. 
Chemical Structure:  
Taste masking 
As large amount of drugs are unpleasant, fast disintegrating drugs usually 
contain medicament in a taste-masked form. The rapid disintegrating drugs 
break downing patient’s oral cavity, thus, releasingactive ingredients which 
directly come in contact with taste buds. 
Amount of 
Drug 
As amount of the drug is an important parameter in the formulation of fast 
dissolving tablet i.e. an optimized amount should be taken during the 
formulation of these tablets, quantity of dose of the drug must be lesser than 
400 mg forinsoluble drugs and less than 60 mg for solubledrugs.  
Mouth feel 
As good mouth feel considered as the important consideration in the 
formulation of FDT’s. So it is important to note that ODT should leave 
minimal or no residue in the mouth after oral administration. 
Sensitivity to 
environmental 
conditions 
It should be kept in mind during the formulation of FDTs that they generally 
should show low sensitivity to environmental conditions such as humidity and 
temperature. 
Hygroscopicity 
Hygroscopicity is one the parameter that should be considered in FDT’s as 
many orally disintegrating dosage forms loose physical integrity under 
standard conditions of temperature and humidity as they are hygroscopic. 
Size of tablet 
The size of the fast dissolving tablet should also consider as prior parameter to 
be considered. The easiest size to handle was larger than 8 mm. Therefore, the 
tablet size that is both easy to take and handle is difficult to reach. 
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Chemical Name: (2R)-N-benzyl-2-acetamido-3-methoxypropanamide 
Molecular Formula: C13H18N2O3 
Generic Name: Lacosamide 
Molecular Weight: 250.298 g/mol 
Category: Anti-epileptic Agents 
Sub-category: Sodium channel Inhibitor 
Percentage Purity: 98.0% - 101.0%  
Description: Lacosamide is a white amorphous powder. 
Solubility: Completely solubilize in Phosphate buffer of Saliva pH 6.8, sparingly 
soluble in water and slightly soluble in acetonitrile and ethanol. 
Stability: Stable under ordinary conditions  
pKa:  12.47 
Log P: 0.728 (Octanol/Water) 
Melting point: 140-146˚C 
Storage: To be stored in well closed, away from heat and damp places. 
Mechanism of action 
 It works by selectively enhancement of slow inactivation of voltage gated 
sodium channels, and helps in the stabilizing of the hyperexcitable neuronal 
brain membranes and also inhibits the neuronal firing.  
 As other antiepileptic drugs works by fast inactivation of the sodium channels 
and hence this lacosamide drug is having its unique mode of action. 
 
Absorption 
Lacosamide is administered by oral route and shows the complete absorption of the 
drug with having no first pass metabolism. In-vivo studies show that lacosamide is 
having 100% bioavailability. The absorption rate and extent are not affected by food 
intake. It shows the reaching of peak plasma concentrations within 4hr after taking a 
single dose (100–800 mg).  
 
Distribution  
As Lacosamide is having low affinity to bound with plasma protein i.e. less than 15% 
and hence the risk of drug-drug interaction is very low. The volume of distribution of 
lacosamide is near about 0.8 L/kg. 
 
Elimination 
The half-life of this drug was found to be near about 13 hr, allowing convenient BID 
dosing. The elimination process follows the first order kinetics which is described by 
the one compartment modelling. Lacosamide is mainly excreted by renal route  
 
Formulations: 
Lacosamide is a drug used in the treatment of partial onset seizures and diabetic 
neuropathic pain.Vimpat is the brand name of the lacosamide drug.  
  
 
Polymer Profile 
 
Guar gum 
 It is a natural occurring polymer, completely soluble in buffer, and is also approved by 
FDA for use as food additive. It has a formula of C10H14N5Na2O12P3 
 
 
. 
 
Fig 3FTIR range of Guar Gum 
 
Table No1: Interpretation of FTIR spectra of Guar Gum 
S.No. Peak cm
-1
 Groups 
1. 3448 Ar-NH2 
2. 873 P=O-Ar Stretching 
3. 522 P=O-Ar bending 
4. 808 P-O-Ar stretching 
5. 472 P-O-Ar Bending 
6.  1014 C-O Acyclic ring 
7. 2924 CH2OH- Ar Stretching 
8.  1654 N-H Bending 
9. 1153 C-N 
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Fig 4 FTIR Spectra of Lacosamide 
Mannitol 
Mannitol is widely used as pharmaceutical excipients such as used as diluent in the 
formulation of tablet and capsule, used as sweetening agent in the mouth dissolving 
tablets mainly, used as a tonicity agent. Mannitol is extracted by the sugar fructose and 
its taste is as sweet as sucrose. Mannitol shows the cooling effect and hence helps in the 
masking of the bitter tastes. 
 
 
Synonyms 
 
D-Mannitol, mannite, manna sugar 
 
IUPAC Name (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol 
Molar mass 182.172 g·mol
−1
 
Appearance White crystalline powder. 
Odor Odorless 
Solubility Soluble in alcohol; water. 
Application in Pharmaceutical formulation: 
 Mannitol is widely accepted excipients used in various pharmaceutical 
formulations. 
 It is used as tablet diluent in different pharmaceutical formulations and since it is 
used in combination with moisture sensitive active ingredients because of its 
non-hygroscopic nature. 
Stability and Storage Conditions: 
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Mannitol is stable when stored in a well closed amber colored container. It should also 
protect by variations in the environmental temperature. 
 
 
Fig 5 FTIR ranges of Mannitol 
Table No: 2 Spectra showing wave no. of Mannitol 
S.No. Peak cm
-1
 Groups 
1. 3398 C-OH Aliphatic 
2. 1288 C-C stretching 
3. 2972 C-H stretching 
4. 1423 C-O stretching 
 
Microcrystalline cellulose: (Frone et al, 2011; Laka et al, 2007) 
Microcrystalline cellulose is widely accepted excipients used as a disintegrants in the 
fast dissolving tablets and used as bulking agent in the food production. 
 
Stability and Storage condition: 
MCC is completely stable in nature, but it is one of the hygroscopic materials. Hence it 
should be stored in the well-closed container in a cool and dry place. 
 
  
 
Fig 6 FTIR Spectra of MC 
 
Table No 3: Interpretation of MCC by FTIR spectra 
S.No. Peak cm
-1
 Groups 
1. 2362 CH2-OH 
2. 2927 CHO aromatic 
3. 1645 C-H stretching 
4. 1460 C-OH Symmetric 
5. 997 C-OH Asymmetric 
6. 1159 C-O Stretching 
7. 574 C-O-C bending 
8. 763 C-C-O bending 
 
 Starch 
Starch is one of the widely found substances which are stored in plants. Starch is widely 
accepted excipients have been very useful in tablet production due to their inertness, 
cheapness and utilization as fillers, binders, disintegrants and glidants. Starch is mainly 
used in the formulation of tablet as binders, and disintegrants. 
 
 
 
Functional category of Starch: 
 Glidant. 
 Tablet and capsule diluent. 
 Tablet and capsule disintegrants. 
 
  
Application in Pharmaceutical formulation or Technology: 
1. Starch is mostly or commonly used excipients in the tablet formulation. 
2. It is used as food additive and is generally regarded as an essentially non-toxic and 
non-irritant material. 
 
Stability and Storage Conditions: 
Starch should be stored in an amber colored container & in a cool & dry place. 
  
Fig .7 FTIR Spectra of Starch 
 
 
Table No 4: Interpretation of Starch by FTIR spectra 
S.No. Peak cm
-1
 Groups 
1. 2364 CH2-OH stretching 
2. 1463 C-H2 stretching 
3. 1450 C-OH symmetric 
4. 1165 C-O stretching 
5. 979 C-OH Asymmetric 
6. 763 C-C-O bending 
7. 572 C-O-C bending 
 
Talc 
Talc is a mineral commonly occurring and consists of magnesium, silicon and oxygen. 
It is a substance mainly found in various cosmetic products such as baby powder, adult 
body powders and facial powders.  
 
 
  
 
 
Chemical Name 
Altalc, hydrous magnesium calcium silicate, hydrous 
magnesium silicate, 
IUPAC Name dioxosilane;oxomagnesium;hydrate 
Molecular formula  Mg3Si4O10(OH)2 
Molar weight 379.259 g/mol 
Appearance White to grayish-white very fine crystalline powder. 
Density 2.70-2.80 g/cm
3 
Melting point 900-1000 °C 
Solubility Freely soluble in water. 
. 
 
Stability and Storage condition: Talc is very stable in nature and it can be sterilized by 
heating process at 160°C for not less than 1hour, it may also be sterilized by exposure to 
ethylene oxide or gamma irradiation. It should be stored in well closed container. 
 
Fig 8 FTIR Spectra of Talc 
 
Table No 5: Interpretation of Talc by FTIR spectra 
S.No. Peak cm
-1
 Groups 
1. 1016 C-O stretching 
2. 1670 C=O stretching 
3. 2920            N-H-bending 
4. 2366 N-CH3 stretching 
5. 671 C-N bending 
6. 650 O-CH3 
  
 
Magnesium Stearate 
Magnesium stearate is the compound which is chemically produced having molecular 
formula Mg (C18H35O2)2.  It consists of salt containing 2 anions of stearic acid and one 
magnesium cation.  
 
 
Application in Pharmaceutical formulation 
 Magnesium stearate is often used as an anti-adherentin the manufacture of 
medical tablets, capsules and powders.  
. 
 
Fig.9 FTIR Spectra of Magnesium Stearate 
 
Table No 6: Interpretation of Magnesium Stearate by FTIR spectra  
S.No. Peak cm
-1
 Groups 
1. 3380 O-H stretching 
2. 3470 N-H stretching 
3. 3080 C-H aromatic 
4. 1740 C=O stretching 
5. 1540 C=C aromatic 
 
Vanillin 
Vanillin is a widely used flavouring agent in tablet formulation to provide good feel. 
The molecular formula of vanillin is C8H8O3 
 
 
  
IUPAC Name 4-Hydroxy-3-methoxybenzaldehyde 
Molecular formula  C8H8O3 
Molar mass 152.15 g mol
−1
 
Appearance White crystalline form 
Odor Vanilla, Sweet, Balsamic, Pleasant 
Density 1.056 g cm
−3
 
Melting point 81-83 °C, 354-356 K, 178-181 °F 
Boiling point 285 °C, 558 K, 545 °F 
Solubility in water 10 g dm
−3
 
Table No 7: List of equipments 
S.No. Name of instrument Source 
1 
Fourier Transform 
Infrared Spectroscopy 
IR Affinity 1, Shimadzu, Japan 
2 
UltravioletVisible 
Spectrophotometer 
U.V. 1800, Shimadzu, Japan 
3 
Tablet compression 
machine 
Rimek Mini- Press- I, Gujarat, India 
4 Dissolution apparatus 
TDT-08L, Electrolab, Dissolution Tester USP, 
Mumbai, India 
5 Monsanto Hardness Tester Vinsyst Technologies, Mumbai, India 
6 VernierCaliper Mitutoyo Corporation, China 
7 Test Sieve (60) Scientific Engineering Corp, Delhi. 
8 Digital Balance AW 120, Shimadzu Corporation, Japan 
 
Methodology 
During development of any formulation; its exact analytical technique and its details are 
highly desirable, so for the same, firstly pure drug was studied for its characteristics and 
its standard curve was prepared. 
Preparation of Lacosamide Calibration Curve 
The standard curve of lacosamide is prepared by firstly preparing the stock solution of 
100 mcg/ml. The stock solution was prepared by taking accurately weighed 5 mg of 
drug (Lacosamide) and dissolve in the 50 ml of phosphate buffer of pH 6.9 in a 
volumetric flask. From the above prepared stock solution, different dilutions such as (2, 
4, 6, 8, 10, 12 mcg/ml) were prepared and the absorbance at which calibration curve has 
to be obtained was scanned at 206 nm in UV Spectrophotometer.  
Results and Discussion 
 
Preformulation studies: 
 Identification of drug 
Lacosamide was identified by several methods like infrared spectroscopy and ultraviolet 
spectroscopy.  
 
Infrared spectrum: 
In FTIR spectroscopy, firstly the pellets of KBr and drug were prepared and then 
examined under Shimadzu8400S (4000-400/cmIR spectrophotometer (Shimadzu, 
Japan). 
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Figure 10: FTIR spectra of Lacosamide 
 
Table No 8: Interpretation of FTIR spectra of Lacosamide 
S.No. Peak cm
-1
 Groups 
1. 3400cm
-1 
O-H stretching 
2. 3300cm
-1 
N-H stretching 
3. 3040cm
-1 
C-H aromatic 
4. 1640cm
-1 
C=O stretching 
5. 1550cm
-1 
C=Caromatic 
6. 1540cm
-1 
N-H bending 
7. 1240cm
-1 
C-N stretching 
8. 1220cm
-1 
C-O stretching 
9. 1160cm
-1 
C-F stretching 
 
Melting point determination: 
The Lacosamide melting point can be measured by using thieles tube method. In this 
method 300 ml of heavy paraffin was filled in thieles tube, and the drug filled in a 
capillary tube of which one end is sealed with the help of flame, and was tied with the 
thermometer and was suspended in thieles tube filled with paraffin.  
Table No 21: Melting Point of Lacosamide 
S.No. Reported Observed 
1. 140-146ºC 145ºC 
 
 
 
Solubility determination: 
The solubility study of drug was performed in different solvent (e.g. Ethanol, Phosphate 
buffer pH6.8 etc).A known quantity of drug, i.e.10 mg was transferred in a series of 
different solvents having volume 5 ml in different test tubes. 
Procedure: 
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The partition coefficient of drug (Lacosamide) was determined in solvent system: n-
octanol/phosphate buffer pH (6.8). Accurately weighed quantity of drug (10 mg) taken 
in one stoppered glass vial containing 5 ml ofoctanol, 5ml of phosphate buffer was 
added to the vial.  
Pw/o =(C aqueous / C organic) 
Where, 
C organic - Concentration of drug in organic phase. 
C aqueous - Concentration of drug in aqueous phase. 
Po/w - Partition coefficient of drug in oil in water system. 
Pw/o - Partition coefficient of drug in water in oil system. 
Same process was applied with n-octanol / distilled water system partition coefficient 
determination. 
Methods of Analysis 
 
Preparation of calibration curve: 
The standard curve is prepared by preparing the stock solution of 100 mcg/ml by 
dissolving accurately weighed 5 mg of Lacosamide in 50 ml of Phosphate buffer pH- 
6.8 in a volumetric flask
 
1) Formula for preparing fast dissolving tablet using Guargum, Mannitoland 
MCC 
Ingredients (mg) 
Formulation code 
F1 
Lacosamide 50 
Guar gum 10 
Mannitol 100 
Microcrystalline cellulose 10 
Aspartame 4 
Starch 20 
Talc 4 
Magnesium stearate 2 
Vanilline q.s. 
Total weight (mg) 200 
 
2) Formula for preparing fast dissolving tablets using Guargum and increasing 
concentration of Mannitol 
 
Ingredients (mg) 
Formulation code 
F2 
Lacosamide 50 
Guar gum 10 
Mannitol 110 
Aspartame 4 
Starch 20 
Talc 4 
Vanilline q.s 
Total weight (mg) 200 
 
Method of preparation of fast dissolving tablets:  
By Direct Compression Technique: 
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Tablets containing Lacosamide were formulated using various superdisintegrants like 
Guar gum, MCC in concentrations ranging from 5-10%. The tablets were prepared by 
direct compression method. 
Procedure: 
1. All the ingredients were passed through a sieve number 40 prior to mixing. 
2. Lacosamide, MCC, Mannitol and the superdisintegrants were properly mixed for 
30min in a suitable container to obtain a uniform blend. The blend was further 
lubricated with magnesium stearate and talc for 5min 
 
Evaluation of fast dissolving tablets  
Weight variation:  
Weight variation was determined to know whether different batches of tablets have 
uniformity. 
Table No 9: Weight variation specification 
IP/BP Limit USP 
80 mg or less 10% 130mg or less 
More than 80mg or Less than 250mg 7.5% 130mg to 324mg 
250mg or more 5% More than 324mg 
 
 
Tablet Thickness and Diameter: 
Thickness and diameter of tablets were important for uniformity of tablet size. 
Thickness and diameter were measured using VernierCalipers.  
 
Friability (F):  
Friability of the tablet determined using Roche friabilator. This device subjects the 
tablet to the combined effect of abrasion and shock in a plastic chamber revolving at 25 
rpm and dropping a tablet at a height of 6 inches in each revolution. Pre weighted 
sample of tablets was placed in the friabilator and were subjected to the 100 revolutions.  
 
 
W initial – W final 
F = --------------------- X 100 
W initial 
 
Table No 10: Friability of different formulation 
S.No Formulation code Friability 
1. F1 0.42 
2. F2 0.49 
3. F3 0.58 
4. F4 0.55 
5. F5 0.56 
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Figure 11: Friability of different formulation 
 
Wetting time 
Two circular tissue papers of 10 cm diameterwere placed in a petri dish having the 
sameinner diameter. 10 mL of phosphate buffersolution pH 6.8 containing a 
watersolubledye, was added to petri dish.  
 
Figure 12Before wetting    Figure 13After wetting 
 
Water absorption ratio 
A piece of tissue paper folded twice was placed in a small petri dish containing 6 ml of 
water. A tablet was put on the paper & the time required for complete wetting was 
measured. 
R = 100 x [Wa – Wb] / Wb 
Where, Wa = weight of tablet after absorption 
Wb = weight of tablet before absorption 
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Figure 14Before Absorption                      Figure 15After Absorption 
 
In-vitro dispersion time 
In-vitrodispersion time was measured by dropping a tablet into a Petri dish containing 
10 ml of phosphate buffer solution pH 6.8 at 37±0.5
0
C. Three tablets from each batch 
were randomly selected and tested. 
 
TableNo 11: In-vitro dispersion time of different formulation 
 
S.No Formulation code In-vitro dispersion time (sec) 
1. F1 56.0±2.28 
2. F2 50.16±1.32 
3. F3 54.33±2.73 
4. F4 52.83±2.56 
5. F5 50.83±1.70 
 
Mean ± S.D. (n=3) 
 
 
Figure 16In-vitro dispersion time of different formulation 
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Figure 17In-vitro dispersion time 
 
Dissolution Studies 
The release rate of lacosamide from mouth dissolving tablets was determined using USP 
Dissolution Testing Apparatus II (Paddle type).  
 
 
Table 12:Details of Dissolution Test 
S.No Requirement Specification 
1. Apparatus USP Type II 
2. Volume of medium 900 ml 
3. Temperature 37±0.5
0
C 
4. Paddle Speed 50 rpm 
5. Dissolution medium used 6.8 phosphate buffer 
6. A liquid  taken at each time interval 5 ml 
 
Table 13: Comparative cumulative drug release of different formulations 
S. No 
Time 
(Min) 
Comparative Cumulative Release of Different Formulations 
F1 F2 F3 F4 F5 
1. 0 0 0 0 0 0 
2. 2 15.15±0.73 18.96±0.73 28.34±1.26 18.21±0.67 20.21±0.77 
3. 4 29.53±0.32 35.14±0.39 40.08±0.32 35.85±0.31 42.85±0.40 
4. 6 44.79±0.96 50.71±0.50 52.7±0.77 48.93±0.49 60.90±0.50 
5. 8 60.09±0.73 62.64±0.57 64.05±0.95 56.24±0.31 72.20±0.55 
6. 10 74.74±0.44 78.80±0.37 76.25±0.50 78.8±0.81 84.10±0.27 
7. 12 92.94±0.69 99.86±0.54 90.17±1.14 92.66±0.47 95.66±0.50 
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a
Mean ± S.D.(n=3) 
 
 
Figure 18Comparative study of cumulative release of different formulations 
 
 
Figure 19 Comparative study of cumulativerelease of different formulations
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Conclusion 
The fast dissolving tablets were successfully prepared bydirect compression method of the 
Lacosamideusing superdisintegrants and the objective of this study was achieved. By the in-
vitro disintegration, it is concluded that formulation preparedby Guar Gum (10%)showed the 
fast disintegration time than the MCC. So it represent that the use of superdisintegrants, it 
increases the release of the drugLacosamide. Therefore, it may be concluded that mouth 
dissolving tablet was suitable drug delivery system forLacosamide.  Thus, the “patient-
friendly dosage form” especially for pediatric, geriatric, bedridden, and non-cooperative 
patients, can be successfully formulated using this technology, and also provides faster and 
better drug release, thereby, improving the bioavailability of drug as compared to the 
conventional marketed formulation.The objective of present study was to prepare and 
evaluate the mouth dissolving tablet of Lacosamideusing Super disintegrants like Guar Gum, 
and Microcrystalline Cellulosein different concentrations by Direct Compression 
method.Lacosamide mouth dissolving tablets prepared were evaluated for Pre-compressional 
and Post compressional parameters. The Pre-compressional parameters evaluated are bulk 
density, true density, angle of repose and Carr’s index. The various evaluation parameters are 
studied such as Hardness, weight variation, friability, In-Vitro dispersion, Drug content 
uniformity and In-vitro drug release studies were carried out for all the formulation. All the 
Formulations gave the result within the official limits. The prepared mouth dissolving tablet 
shows the properties of fast disintegration time (35sec. to128 sec). Different drug release 
kinetics model were applied for selecting batches stability studies, showed that there was no 
any significant change in residual drug content mouth dissolving tablets. 
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